Overcoming leukemia heterogeneity by combining T cell engaging bispecific antibodies

BACKGROUND: Leukemia represents about 5% of all human cancers. Despite advances in therapeutics, a substantial number of patients succumb to the disease. Several subtypes of leukemia are inherently more resistant to treatment despite intensive chemotherapy or targeted therapy. METHODS: Here we descr...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoseini, Sayed Shahabuddin, Espinosa-Cotton, Madelyn, Guo, Hong-fen, Cheung, Nai-Kong V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Basic Tumor Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689592/
https://www.ncbi.nlm.nih.gov/pubmed/33239418
http://dx.doi.org/10.1136/jitc-2020-001626

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689592/
https://www.ncbi.nlm.nih.gov/pubmed/33239418
http://dx.doi.org/10.1136/jitc-2020-001626

Ejemplares similares